BioWorld

Dec. 3, 2007

Fate Tempts VCs With Viable Stem Cell Business Model

Amid a flurry of stem cell news, Fate Therapeutics raised $12 million in a Series A financing to pursue in vivo and ex vivo modulation of adult stem cells. (BioWorld Today) Read More

Panel: FDA's Science 'Weak'; Increased Funding Needed

New Discoveries May Aid HIV Prevention, Treatment

FDA Amendments Act - Detrimental To Advertising Prescription Drug

Financings Roundup

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for March 26, 2026.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026